Education
About Us
Working with TipRanks
Follow Us
Processa Pharmaceuticals (PCSA)
NASDAQ:PCSA
PCSA Stock Chart & Stats
$0.30
-$0.13(-13.68%)
At close: 4:00 PM EST
$0.30
-$0.13(-13.68%)
Day’s Range― - ―
52-Week Range$0.15 - $1.50
Previous CloseN/A
Volume113.34K
Average Volume (3M)17.04M
Market Cap
$17.42M
Enterprise Value-$3.72M
Total Cash (Recent Filing)$6.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding50,349,148
10 Day Avg. Volume46,022,589
30 Day Avg. Volume17,044,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.59
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-0.21
Enterprise Value/Revenue-0.30
Enterprise Value/Gross Profit-0.60
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$1.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPositive interim data from the NGC-Cap mid-stage trial should constitute a meaningful value inflection point.
Licensing AgreementsBinding term sheet signed with Intact Therapeutics to license PCS12852 for gastroparesis, with potential financial benefits including option exercise fee and milestone payments.
Strategic InvestmentsProcessa recently announced that it secured a strategic investment and is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives.
Bears Say
Compliance IssuesProcessa has received a notice from the NASDAQ exchange indicating that it is not currently in compliance with the minimum bid price requirement due to the low current share price.
Equity DilutionThe company obtained roughly $1.1M in net proceeds from the sale of approximately 5.5M shares of common stock at $0.23 per share, which reflects recent and projected equity dilution.
Funding ChallengesAdditional capital will likely be required to fully fund the ongoing Phase 2 trial, despite having sufficient cash to fund into 1Q26.
Processa Pharmaceuticals News
PCSA FAQ
What was Processa Pharmaceuticals’s price range in the past 12 months?
Processa Pharmaceuticals lowest stock price was $0.15 and its highest was $1.50 in the past 12 months.
What is Processa Pharmaceuticals’s market cap?
Processa Pharmaceuticals’s market cap is $17.42M.
When is Processa Pharmaceuticals’s upcoming earnings report date?
Processa Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 269 days.
How were Processa Pharmaceuticals’s earnings last quarter?
Processa Pharmaceuticals released its earnings results on Nov 05, 2025. The company reported -$0.072 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.008.
Is Processa Pharmaceuticals overvalued?
According to Wall Street analysts Processa Pharmaceuticals’s price is currently Undervalued.
Does Processa Pharmaceuticals pay dividends?
Processa Pharmaceuticals does not currently pay dividends.
What is Processa Pharmaceuticals’s EPS estimate?
Processa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Processa Pharmaceuticals have?
Processa Pharmaceuticals has 50,349,148 shares outstanding.
What happened to Processa Pharmaceuticals’s price movement after its last earnings report?
Processa Pharmaceuticals reported an EPS of -$0.072 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of Processa Pharmaceuticals?
Currently, no hedge funds are holding shares in PCSA
Company Description
Processa Pharmaceuticals
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
PCSA Stock 12 Month Forecast
Average Price Target
$1.00
▲(233.33% Upside)
Technical Analysis
Ownership Overview
1.37% Insiders
0.16% Mutual Funds
0.31% Other Institutional Investors
98.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---